This webinar discusses the new indication of a previously approved agent, Eltrombopag, in the treatment of children one-year and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Eltrombopag was approved by the FDA in 2008 for use in adult patients with the same condition.
Cindy Neunert, MD, MSCS, Columbia University Medical Center, New York, NY
Lori A. Ehrlich, MD, PhD, Medical Officer, Division of Hematology Products, OHOP/OND/CDER/FDA, Silver Spring, MD
Ellis J. Neufeld, MD, PhD, Associate Chief, Division of Hematology/Oncology, Egan Family Foundation Chair in Transitional Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA